Stocks and Investing
Stocks and Investing
Thu, February 23, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Terence Flynn Maintained (UTHR) at Buy with Decreased Target to $320 on, Feb 23rd, 2023
Terence Flynn of Morgan Stanley, Maintained "United Therapeutics Corporation" (UTHR) at Buy with Decreased Target from $330 to $320 on, Feb 23rd, 2023.
Terence has made no other calls on UTHR in the last 4 months.
There are 5 other peers that have a rating on UTHR. Out of the 5 peers that are also analyzing UTHR, 0 agree with Terence's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with Terence
- Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $300 on, Wednesday, January 11th, 2023
- Ashwani Verma of "UBS" Initiated at Strong Buy and Held Target at $320 on, Tuesday, December 6th, 2022
- Chris Shibutani of "Goldman Sachs" Initiated at Strong Sell and Held Target at $230 on, Monday, December 5th, 2022
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $375 on, Thursday, November 3rd, 2022
- Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $265 on, Thursday, November 3rd, 2022
Contributing Sources